Drug discovery and computational strategies in the multitarget drugs era

The pharmaceutical industry is increasingly joining chemoinformatics in the search for the development of new drugs to be used in the treatment of diseases. These computational studies have the advantage of being less expensive and optimize the study time, and thus the interest in this area is increasing. Among the techniques used is the development of multitarget directed ligands (MTDLs), which has become an ascending technique, mainly due to the improvement in the quality of treatment involving several drugs. Multitarget therapy is more effective than traditional drug therapy that emphasizes maximum selectivity for a single target. In this review a multitarget drug survey was carried out as a promising strategy in several important diseases: neglected diseases, neurodegenerative diseases, AIDS, and cancer. In addition, we discuss Computer-Aided Drug Design (CADD) techniques as a tool in the projection of multitarget compounds against these diseases.

[1]  Feng Luan,et al.  A ligand-based approach for the in silico discovery of multi-target inhibitors for proteins associated with HIV infection. , 2012, Molecular bioSystems.

[2]  J. Levine,et al.  Surfing the p53 network , 2000, Nature.

[3]  A Lavecchia,et al.  Virtual screening strategies in drug discovery: a critical review. , 2013, Current medicinal chemistry.

[4]  Adrian L Gill,et al.  A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. , 2007, Current topics in medicinal chemistry.

[5]  N. Jain,et al.  3-Aryl-1-phenyl-1H-pyrazole derivatives as new multitarget directed ligands for the treatment of Alzheimer's disease, with acetylcholinesterase and monoamine oxidase inhibitory properties , 2013, EXCLI journal.

[6]  Peter Kolb,et al.  Identifying modulators of CXC receptors 3 and 4 with tailored selectivity using multi-target docking. , 2015, ACS chemical biology.

[7]  Yuzong Chen,et al.  Olaparib hydroxamic acid derivatives as dual PARP and HDAC inhibitors for cancer therapy. , 2017, Bioorganic & medicinal chemistry.

[8]  Azizeh Abdolmaleki,et al.  Computer Aided Drug Design for Multi-Target Drug Design: SAR /QSAR, Molecular Docking and Pharmacophore Methods. , 2017, Current drug targets.

[9]  Feng Luan,et al.  Multi-target inhibitors for proteins associated with Alzheimer: in silico discovery using fragment-based descriptors. , 2013, Current Alzheimer research.

[10]  K. Bae,et al.  Protective action of honokiol, administered orally, against oxidative stress in brain of mice challenged with NMDA. , 2007, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[11]  Xi-can Tang,et al.  Huperzine A exhibits anti‐inflammatory and neuroprotective effects in a rat model of transient focal cerebral ischemia , 2008, Journal of neurochemistry.

[12]  G. Church,et al.  Identifying regulatory networks by combinatorial analysis of promoter elements , 2001, Nature Genetics.

[13]  Lin Zhou,et al.  Rational design and synthesis of highly potent anti-acetylcholinesterase activity huperzine A derivatives. , 2009, Bioorganic & medicinal chemistry.

[14]  S. Brooker,et al.  Cutaneous leishmaniasis. , 2007, The Lancet. Infectious diseases.

[15]  Weiwei Xue,et al.  The Human Kinome Targeted by FDA Approved Multi-Target Drugs and Combination Products: A Comparative Study from the Drug-Target Interaction Network Perspective , 2016, PloS one.

[16]  Andrea Armirotti,et al.  Multitarget drug discovery for Alzheimer's disease: triazinones as BACE-1 and GSK-3β inhibitors. , 2015, Angewandte Chemie.

[17]  Daniel Cappel,et al.  Accurate Binding Free Energy Predictions in Fragment Optimization , 2015, J. Chem. Inf. Model..

[18]  Gabriela Chiosis,et al.  Identification of potent water soluble purine-scaffold inhibitors of the heat shock protein 90. , 2006, Journal of medicinal chemistry.

[19]  Gabriela Chiosis,et al.  Evaluation of 8-arylsulfanyl, 8-arylsulfoxyl, and 8-arylsulfonyl adenine derivatives as inhibitors of the heat shock protein 90. , 2005, Journal of medicinal chemistry.

[20]  J. Choe,et al.  Characterization of Imidazo[4,5-d]Pyridazine Nucleosides as Modulators of Unwinding Reaction Mediated by West Nile Virus Nucleoside Triphosphatase/Helicase: Evidence for Activity on the Level of Substrate and/or Enzyme , 2002, Antimicrobial Agents and Chemotherapy.

[21]  Richard Morphy,et al.  Designed Multiple Ligands. An Emerging Drug Discovery Paradigm , 2006 .

[22]  Humberto González-Díaz,et al.  First computational chemistry multi-target model for anti-Alzheimer, anti-parasitic, anti-fungi, and anti-bacterial activity of GSK-3 inhibitors in vitro, in vivo, and in different cellular lines , 2011, Molecular Diversity.

[23]  Christopher M. Overall,et al.  Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy , 2006, Nature Reviews Cancer.

[24]  Aniruddha Datta,et al.  Towards targeted combinatorial therapy design for the treatment of castration-resistant prostate cancer , 2017, BMC Bioinformatics.

[26]  Xinyang Hu,et al.  Baicalin attenuates oxygen-glucose deprivation-induced injury via inhibiting NMDA receptor-mediated 5-lipoxygenase activation in rat cortical neurons. , 2007, Pharmacological research.

[27]  Matthew P. Repasky,et al.  Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. , 2004, Journal of medicinal chemistry.

[28]  Hege S. Beard,et al.  Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. , 2004, Journal of medicinal chemistry.

[29]  Hongmei Wu,et al.  Flavonoids as noncompetitive inhibitors of Dengue virus NS2B-NS3 protease: inhibition kinetics and docking studies. , 2015, Bioorganic & medicinal chemistry.

[30]  Usman Ali Ashfaq,et al.  Molecular Docking Based Screening of Plant Flavonoids as Dengue NS1 Inhibitors , 2014, Bioinformation.

[31]  R. Wolkowicz,et al.  A Multiplexed Cell-Based Assay for the Identification of Modulators of Pre-Membrane Processing as a Target against Dengue Virus , 2015, Journal of biomolecular screening.

[32]  CHUN WEI YAP,et al.  PaDEL‐descriptor: An open source software to calculate molecular descriptors and fingerprints , 2011, J. Comput. Chem..

[33]  H. Zhang,et al.  Huperzine A attenuates mitochondrial dysfunction after middle cerebral artery occlusion in rats , 2008, Journal of neuroscience research.

[34]  Ruixin Zhu,et al.  Multi-target QSAR Study in the Analysis and Design of HIV-1 Inhibitors† , 2010 .

[35]  A. Cavalli,et al.  Toward the Development of Dual‐Targeted Glyceraldehyde‐3‐phosphate Dehydrogenase/Trypanothione Reductase Inhibitors against Trypanosoma brucei and Trypanosoma cruzi , 2014, ChemMedChem.

[36]  Pushpendra Singh,et al.  Multitargeted molecular docking study of plant-derived natural products on phosphoinositide-3 kinase pathway components , 2014, Medicinal Chemistry Research.

[37]  G. Trossini,et al.  Hologram QSAR Studies of Antiprotozoal Activities of Sesquiterpene Lactones , 2014, Molecules.

[38]  Jiansong Fang,et al.  In silico Target Fishing for the Potential Targets and Molecular Mechanisms of Baicalein as an Antiparkinsonian Agent: Discovery of the Protective Effects on NMDA Receptor‐Mediated Neurotoxicity , 2013, Chemical biology & drug design.

[39]  Kishore R. Sakharkar,et al.  Novel phytochemical–antibiotic conjugates as multitarget inhibitors of Pseudomononas aeruginosa GyrB/ParE and DHFR , 2013, Drug design, development and therapy.

[40]  Mayank,et al.  Molecular docking study of natural alkaloids as multi-targeted hedgehog pathway inhibitors in cancer stem cell therapy , 2016, Comput. Biol. Chem..

[41]  Boon Chuan Low,et al.  In-Silico Approaches to Multi-target Drug Discovery , 2010, Pharmaceutical Research.

[42]  A. Díaz,et al.  Leishmaniasis cutánea y herpes zoster multidermatómico , 2013 .

[43]  J. Richard Morphy.  Chapter 10:The Challenges of Multi-Target Lead Optimization , 2012 .

[44]  Feng Luan,et al.  Multi-target drug discovery in anti-cancer therapy: fragment-based approach toward the design of potent and versatile anti-prostate cancer agents. , 2011, Bioorganic & medicinal chemistry.

[45]  A. Barabasi,et al.  Drug—target network , 2007, Nature Biotechnology.

[46]  Jeffrey A Jones,et al.  Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies. , 2018, Blood.

[47]  Richard Morphy,et al.  Fragments, network biology and designing multiple ligands. , 2007, Drug discovery today.

[48]  Rolf Müller,et al.  Crosstalk of oncogenic and prostanoid signaling pathways , 2004, Journal of Cancer Research and Clinical Oncology.

[49]  Demin Zhou,et al.  Honokiol inhibits the inflammatory reaction during cerebral ischemia reperfusion by suppressing NF-κB activation and cytokine production of glial cells , 2013, Neuroscience Letters.

[50]  R. Pérez-Montfort,et al.  Potent and Selective Inhibitors of Trypanosoma cruzi Triosephosphate Isomerase with Concomitant Inhibition of Cruzipain: Inhibition of Parasite Growth through Multitarget Activity , 2016, ChemMedChem.

[51]  L. M. Espinoza-Fonseca.  Targeting MDM2 by the small molecule RITA: towards the development of new multi-target drugs against cancer , 2005, Theoretical Biology and Medical Modelling.

[52]  Martin Krug,et al.  Recent advances in the development of multi-kinase inhibitors. , 2008, Mini reviews in medicinal chemistry.

[53]  Chien-Yu Chen,et al.  Insights into designing the dual-targeted HER2/HSP90 inhibitors. , 2010, Journal of molecular graphics & modelling.

[54]  Cheng Lu,et al.  Macrocyclic compounds as anti-cancer agents: design and synthesis of multi-acting inhibitors against HDAC, FLT3 and JAK2. , 2015, European journal of medicinal chemistry.

[56]  Pushpendra Singh,et al.  Screening and biological evaluation of myricetin as a multiple target inhibitor insulin, epidermal growth factor, and androgen receptor; in silico and in vitro , 2015, Investigational New Drugs.

[57]  B. Cha,et al.  Honokiol increases ABCA1 expression level by activating retinoid X receptor beta. , 2010, Biological & pharmaceutical bulletin.

[58]  E. Edache,et al.  Multivariate QSAR Study of Indole β- Diketo Acid, Diketo Acid and Carboxamide Derivatives as Potent Anti-HIV Agents , 2015 .

[59]  Juan M. Luco,et al.  QSAR Based on Multiple Linear Regression and PLS Methods for the Anti-HIV Activity of a Large Group of HEPT Derivatives , 1997, J. Chem. Inf. Comput. Sci..

[60]  A. Stoppani,et al.  Redox cycling of o-naphthoquinones in trypanosomatids. Superoxide and hydrogen peroxide production. , 1996, Biochemical pharmacology.

[61]  G. Kaushik,et al.  Honokiol induces cytotoxic and cytostatic effects in malignant melanoma cancer cells. , 2012, American journal of surgery.

[62]  B. Stockwell,et al.  Multicomponent therapeutics for networked systems , 2005, Nature Reviews Drug Discovery.

[63]  Xiaomin Luo,et al.  Towards discovering dual functional inhibitors against both wild type and K103N mutant HIV-1 reverse transcriptases: molecular docking and QSAR studies on 4,1-benzoxazepinone analogues , 2006, J. Comput. Aided Mol. Des..

[64]  D F Hoth,et al.  Present status and future prospects for HIV therapies. , 1993, Science.

[65]  F. Andrade-Narváez,et al.  ANIMAL MODELS FOR THE STUDY OF LEISHMANIASIS IMMUNOLOGY , 2014, Revista do Instituto de Medicina Tropical de Sao Paulo.

[66]  Yingbo Li,et al.  Design, synthesis and biological evaluation of quinazoline-phosphoramidate mustard conjugates as anticancer drugs. , 2017, European journal of medicinal chemistry.

[67]  Pushpendra Singh,et al.  Screening of multi-targeted natural compounds for receptor tyrosine kinases inhibitors and biological evaluation on cancer cell lines, in silico and in vitro , 2015, Medical Oncology.

[68]  A. Lauria,et al.  Kinase Inhibitors in Multitargeted Cancer Therapy. , 2017, Current medicinal chemistry.

[69]  H. Tanabe,et al.  A naturally occurring rexinoid, honokiol, can serve as a regulator of various retinoid x receptor heterodimers. , 2012, Biological & pharmaceutical bulletin.

[70]  G. Lai,et al.  Honokiol-induced apoptosis and autophagy in glioblastoma multiforme cells , 2013, Oncology letters.

[71]  R. Chang,et al.  Baicalin can scavenge peroxynitrite and ameliorate endogenous peroxynitrite-mediated neurotoxicity in cerebral ischemia-reperfusion injury. , 2013, Journal of ethnopharmacology.

[72]  M S Mustafa,et al.  Discovery of fifth serotype of dengue virus (DENV-5): A new public health dilemma in dengue control. , 2015, Medical journal, Armed Forces India.

[73]  Pharmacopore hypothesis generation of BACE-1 inhibitors and pharmacophore-driven identification of potent multi-target neuroprotective agents , 2012, Medicinal Chemistry Research.

[74]  Rona R. Ramsay,et al.  A perspective on multi-target drug discovery and design for complex diseases , 2018, Clinical and Translational Medicine.

[75]  Artem Cherkasov,et al.  Best Practices of Computer-Aided Drug Discovery: Lessons Learned from the Development of a Preclinical Candidate for Prostate Cancer with a New Mechanism of Action , 2017, J. Chem. Inf. Model..

[76]  Paola Brun,et al.  Using the TOPS-MODE approach to fit multi-target QSAR models for tyrosine kinases inhibitors. , 2011, European journal of medicinal chemistry.

[77]  In-silico Discovery and Simulated Selection of Multi-target Anti-HIV-1 Inhibitors , 2016 .

[78]  Bruce Tidor,et al.  Additivity in the analysis and design of HIV protease inhibitors. , 2009, Journal of medicinal chemistry.

[79]  Barbara M. Bakker,et al.  Naphthoquinone Derivatives Exert Their Antitrypanosomal Activity via a Multi-Target Mechanism , 2013, PLoS neglected tropical diseases.

[80]  G. Rastelli,et al.  Discovery of Multitarget Antivirals Acting on Both the Dengue Virus NS5-NS3 Interaction and the Host Src/Fyn Kinases. , 2015, Journal of medicinal chemistry.

[81]  Anand Anbarasu,et al.  Flavonoid from Carica papaya inhibits NS2B-NS3 protease and prevents Dengue 2 viral assembly , 2013, Bioinformation.

[82]  Zhibin Li,et al.  CS2164, a novel multi‐target inhibitor against tumor angiogenesis, mitosis and chronic inflammation with anti‐tumor potency , 2017, Cancer science.

[83]  K. Shokat,et al.  Escape from HER family tyrosine kinase inhibitor therapy by the kinase inactive HER3 , 2007, Nature.

[84]  H. Bluyssen,et al.  Identification of STAT1 and STAT3 Specific Inhibitors Using Comparative Virtual Screening and Docking Validation , 2015, PloS one.

[85]  S. Sundar,et al.  Advances in the treatment of leishmaniasis , 2002, Current opinion in infectious diseases.

[86]  T. Efferth,et al.  Cytotoxicity of the bisphenolic honokiol from Magnolia officinalis against multiple drug-resistant tumor cells as determined by pharmacogenomics and molecular docking. , 2014, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[87]  V. Pillay,et al.  Multi-target therapeutics for neuropsychiatric and neurodegenerative disorders. , 2016, Drug discovery today.

[88]  M. U. Mirza,et al.  Structure-based virtual screening and molecular docking for the identification of potential multi-targeted inhibitors against breast cancer , 2017, Breast cancer.

[89]  Yuzong Chen,et al.  Discovery of benzimidazole derivatives as novel multi-target EGFR, VEGFR-2 and PDGFR kinase inhibitors. , 2011, Bioorganic & medicinal chemistry.

[90]  A. Levine,et al.  Surfing the p53 network , 2000, Nature.

[91]  C. Sadasivan,et al.  Designing of multi-target-directed ligands against the enzymes associated with neuroinflammation: an in silico approach , 2013 .

[92]  M. Verdonk,et al.  A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. , 2007, Current topics in medicinal chemistry.

[93]  Matthew P. Repasky,et al.  Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. , 2006, Journal of medicinal chemistry.

[94]  B. Dong,et al.  Huperzine A for Alzheimer's disease. , 2008, The Cochrane database of systematic reviews.

[95]  R. K. Gordon,et al.  The NMDA receptor ion channel: a site for binding of huperzine A , 2001, Journal of applied toxicology : JAT.

[96]  P. Lansbury.  Back to the future: the 'old-fashioned' way to new medications for neurodegeneration , 2004, Nature Reviews Neuroscience.

[97]  M. Berger,et al.  Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. , 2006, Cancer research.

[98]  Yuzong Chen,et al.  Exploration of acridine scaffold as a potentially interesting scaffold for discovering novel multi-target VEGFR-2 and Src kinase inhibitors. , 2011, Bioorganic & medicinal chemistry.

[99]  W. Chua,et al.  Computational design of disulfide cyclic peptide as potential inhibitor of complex NS 2 BNS 3 dengue virus protease , 2012 .

[100]  Takeshi Yamazaki,et al.  Cheminformatics Modeling of Adverse Drug Responses by Clinically Relevant Mutants of Human Androgen Receptor , 2016, J. Chem. Inf. Model..

[101]  Rui Wang,et al.  Molecular dynamics simulations of interaction between protein-tyrosine phosphatase 1B and a bidentate inhibitor , 2006, Acta Pharmacologica Sinica.

[102]  E. Coy-Barrera,et al.  In-Silico Analyses of Sesquiterpene-Related Compounds on Selected Leishmania Enzyme-Based Targets , 2014, Molecules.